Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma
Article first published online: 15 MAR 2013
© 2013 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 15, Issue 6, pages 428–434, June 2013
How to Cite
J Clin Hypertens (Greenwich).2013;15:428–434©2013 Wiley Periodicals, Inc.
- Issue published online: 4 JUN 2013
- Article first published online: 15 MAR 2013
- Manuscript Accepted: 29 JAN 2013
- Manuscript Revised: 28 JAN 2013
- Manuscript Received: 4 DEC 2012
- the National Center for Research Resources
- National Center for Advancing Translational Sciences
- National Institutes of Health. Grant Number: grant No. KL2TR000139
Pheochromocytomas and paragangliomas are rare tumors with high morbidity rates caused by excessive catecholamine secretion, even though the majority of tumors are benign. The use of perioperative blockade regimens, together with improved surgical techniques, has greatly impacted the perioperative morbidity associated with these tumors. The old dogma of the “tumor of tens” no longer holds true. For example, at least one third of all pheochromocytomas and paragangliomas are hereditary, with mutations in 1 of 10 well-characterized susceptibility genes, and one quarter of all tumors are malignant. This review focuses on the perioperative management of pheochromocytoma and paragangliomas and the clinical implications of the associated genetic mutations.